Ning Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ning Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Ni Fan
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, NO. 126, Xian Tai Street, Changchun, 130033, Jilin, China
1 shared publication Chunni Fan
Department of Breast Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
1 shared publicationChun‐Ni Fan
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
1 shared publication- Dongmei Li
Department of Urology, Nanjing Drum Tower Hospital, State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu 210008, China; Jiangsu Key Laboratory of Molecular Medicine, Division of Anatomy and Histo-embryology, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China
1 shared publication - L Y Yang
Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Sciences, Medical School, Nanjing University, Nanjing, Jiangsu 210093,China
1 shared publication Lei Ma
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 21 (8) , 713-723
NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma
Background: NONO-TFE3 translocation renal cell carcinoma (tRCC), one of the RCCs that are associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 tRCCs), involves an X chromosome inversion between NONO and TFE3 with the characteristics of endonuclear aggregation of NONO-TFE3 fusion protein. The oncogenic mechanisms of NONO-TFE3 fusion have not yet been fully elucidated. Objective: This study aimed at investigating the mechanism of NONO-TFE3 fusion regulating HIF1A as well as the role of HIF-1α in the progression of NONO-TFE3 tRCC under hypoxia. Methods: Immunohistochemistry and Western Blotting assays were performed to profile HIF-1α expression in renal clear cell carcinoma (ccRCC) or in Xp11.2 tRCC. Chromatin immunoprecipitation (ChIP), a luciferase reporter assay, and real-time quantitative PCR (RT-qPCR) were used to evaluate the regulation of HIF1A expression by NONO-TFE3 fusion. Then, the flow cytometry analysis, tube formation assays, and cell migration assays were used as well as glucose or lactic acid levels were measured to establish the impact of HIF-1α on the progression of NONO-TFE3 tRCC. Besides, the effect of HIF-1α inhibitor (PX-478) on UOK109 cells was analyzed. Results: We found that HIF1A was the target gene of NONO-TFE3 fusion. In UOK109 cells, which were isolated from NONO-TFE3 tRCC samples, NONO-TFE3 fusion promoted aerobic glycolysis and angiogenesis by up-regulating the expression of HIF-1α under hypoxia. Furthermore, the inhibition of HIF-1α mediated by PX-478 suppressed the development of NONO-TFE3 tRCC under hypoxia. Conclusion: HIF-1α is a potential target for therapy of NONO-TFE3 tRCC under hypoxia.
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 21 (8) , 713-723
NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma
Background: NONO-TFE3 translocation renal cell carcinoma (tRCC), one of the RCCs that are associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 tRCCs), involves an X chromosome inversion between NONO and TFE3 with the characteristics of endonuclear aggregation of NONO-TFE3 fusion protein. The oncogenic mechanisms of NONO-TFE3 fusion have not yet been fully elucidated. Objective: This study aimed at investigating the mechanism of NONO-TFE3 fusion regulating HIF1A as well as the role of HIF-1α in the progression of NONO-TFE3 tRCC under hypoxia. Methods: Immunohistochemistry and Western Blotting assays were performed to profile HIF-1α expression in renal clear cell carcinoma (ccRCC) or in Xp11.2 tRCC. Chromatin immunoprecipitation (ChIP), a luciferase reporter assay, and real-time quantitative PCR (RT-qPCR) were used to evaluate the regulation of HIF1A expression by NONO-TFE3 fusion. Then, the flow cytometry analysis, tube formation assays, and cell migration assays were used as well as glucose or lactic acid levels were measured to establish the impact of HIF-1α on the progression of NONO-TFE3 tRCC. Besides, the effect of HIF-1α inhibitor (PX-478) on UOK109 cells was analyzed. Results: We found that HIF1A was the target gene of NONO-TFE3 fusion. In UOK109 cells, which were isolated from NONO-TFE3 tRCC samples, NONO-TFE3 fusion promoted aerobic glycolysis and angiogenesis by up-regulating the expression of HIF-1α under hypoxia. Furthermore, the inhibition of HIF-1α mediated by PX-478 suppressed the development of NONO-TFE3 tRCC under hypoxia. Conclusion: HIF-1α is a potential target for therapy of NONO-TFE3 tRCC under hypoxia.
- 2 April 2019
- Published by Spandidos Publications in Oncology Reports
- Vol. 41 (6) , 3313-3324
Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple‑negative breast cancer: An in silico study
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited treatment options combined with poor rates of survival. Given the lack of appropriate prognostic biomarkers for TNBC patients, the present study aimed to identify potential dysregulated miRNAs capable of providing a diagnosis and predicting overall survival for TNBC patients. A total of 289 miRNAs were aberrantly regulated in TNBC tissue compared to adjacent, non-cancerous tissues and 96 microRNAs (miRNAs) in TNBC compared with non-triple-negative breast cancer (nTNBC) samples. Receiver operating characteristic (ROC) curve analysis suggested that 4 miRNAs (hsa-miR-10a, hsa-miR-18a, hsa-miR-135b and hsa-miR-577) had diagnostic value [area under curve (AUC) >0.8]. A 4-miRNA signature consisting of hsa-miR-148b, hsa-miR-203a, hsa-miR-203b and hsa-miR-3922 was constructed for prediction of prognosis. A multivariate Cox's proportional hazards regression model indicated that the 4-miRNA signature was an independent prognostic factor of other clinical variables in patients with TNBC. Functional analysis of the target genes of the miRNA signature demonstrated that the prolactin signaling pathway and miRNAs in cancer were significantly enriched. In conclusion, the results in the present study may highlight efficient biomarkers for the diagnosis of TNBC and its prognosis. In-depth exploitation of these miRNAs will help define and develop novel molecular therapeutic strategies and improve prognosis for TNBC patients.
- 2 April 2019
- Published by Spandidos Publications in Oncology Reports
- Vol. 41 (6) , 3313-3324
Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple‑negative breast cancer: An in silico study
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited treatment options combined with poor rates of survival. Given the lack of appropriate prognostic biomarkers for TNBC patients, the present study aimed to identify potential dysregulated miRNAs capable of providing a diagnosis and predicting overall survival for TNBC patients. A total of 289 miRNAs were aberrantly regulated in TNBC tissue compared to adjacent, non-cancerous tissues and 96 microRNAs (miRNAs) in TNBC compared with non-triple-negative breast cancer (nTNBC) samples. Receiver operating characteristic (ROC) curve analysis suggested that 4 miRNAs (hsa-miR-10a, hsa-miR-18a, hsa-miR-135b and hsa-miR-577) had diagnostic value [area under curve (AUC) >0.8]. A 4-miRNA signature consisting of hsa-miR-148b, hsa-miR-203a, hsa-miR-203b and hsa-miR-3922 was constructed for prediction of prognosis. A multivariate Cox's proportional hazards regression model indicated that the 4-miRNA signature was an independent prognostic factor of other clinical variables in patients with TNBC. Functional analysis of the target genes of the miRNA signature demonstrated that the prolactin signaling pathway and miRNAs in cancer were significantly enriched. In conclusion, the results in the present study may highlight efficient biomarkers for the diagnosis of TNBC and its prognosis. In-depth exploitation of these miRNAs will help define and develop novel molecular therapeutic strategies and improve prognosis for TNBC patients.
- Open Access
- 27 September 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-12
Systematic analysis of lncRNA–miRNA–mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer
Increasing evidence has underscored the role of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the development and progression of tumors. Nevertheless, lncRNA biomarkers in lncRNA-related ceRNA network that can predict the prognosis of breast cancer (BC) are still lacking. The aim of our study was to identify potential lncRNA signatures capable of predicting overall survival (OS) of BC patients. The RNA sequencing data and clinical characteristics of BC patients were obtained from the Cancer Genome Atlas database, and differentially expressed lncRNA (DElncRNAs), DEmRNAs, and DEmiRNAs were then identified between BC and normal breast tissue samples. Subsequently, the lncRNA–miRNA–mRNA ceRNA network of BC was established, and the gene oncology enrichment analyses for the DEmRNAs interacting with lncRNAs in the ceRNA network was implemented. Using univariate and multivariate Cox regression analyses, a four-lncRNA signature was developed and used for predicting the survival in BC patients. We applied receiver operating characteristic analysis to assess the performance of our model. A total of 1061 DElncRNAs, 2150 DEmRNAs, and 82 DEmiRNAs were identified between BC and normal breast tissue samples. A lncRNA–miRNA–mRNA ceRNA network of BC was established, which comprised of 8 DEmiRNAs, 48 DElncRNAs, and 10 DEmRNAs. Further gene oncology enrichment analyses revealed that the DEmRNAs interacting with lncRNAs in the ceRNA network participated in cell leading edge, protease binding, alpha-catenin binding, gamma-catenin binding, and adenylate cyclase binding. A univariate regression analysis of the DElncRNAs revealed 7 lncRNAs (ADAMTS9-AS1, AC061992.1, LINC00536, HOTAIR, AL391421.1, TLR8-AS1 and LINC00491) that were associated with OS of BC patients. A multivariate Cox regression analysis demonstrated that 4 of those lncRNAs (ADAMTS9-AS1, LINC00536, AL391421.1 and LINC00491) had significant prognostic value, and their cumulative risk score indicated that this 4-lncRNA signature independently predicted OS in BC patients. Furthermore, the area under the curve of the 4-lncRNA signature associated with 3-year survival was 0.696. The current study provides novel insights into the lncRNA-related ceRNA network in BC and the 4 lncRNA biomarkers may be independent prognostic signatures in predicting the survival of BC patients.
- 27 September 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-12
Open AccessSystematic analysis of lncRNA–miRNA–mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer
Increasing evidence has underscored the role of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the development and progression of tumors. Nevertheless, lncRNA biomarkers in lncRNA-related ceRNA network that can predict the prognosis of breast cancer (BC) are still lacking. The aim of our study was to identify potential lncRNA signatures capable of predicting overall survival (OS) of BC patients. The RNA sequencing data and clinical characteristics of BC patients were obtained from the Cancer Genome Atlas database, and differentially expressed lncRNA (DElncRNAs), DEmRNAs, and DEmiRNAs were then identified between BC and normal breast tissue samples. Subsequently, the lncRNA–miRNA–mRNA ceRNA network of BC was established, and the gene oncology enrichment analyses for the DEmRNAs interacting with lncRNAs in the ceRNA network was implemented. Using univariate and multivariate Cox regression analyses, a four-lncRNA signature was developed and used for predicting the survival in BC patients. We applied receiver operating characteristic analysis to assess the performance of our model. A total of 1061 DElncRNAs, 2150 DEmRNAs, and 82 DEmiRNAs were identified between BC and normal breast tissue samples. A lncRNA–miRNA–mRNA ceRNA network of BC was established, which comprised of 8 DEmiRNAs, 48 DElncRNAs, and 10 DEmRNAs. Further gene oncology enrichment analyses revealed that the DEmRNAs interacting with lncRNAs in the ceRNA network participated in cell leading edge, protease binding, alpha-catenin binding, gamma-catenin binding, and adenylate cyclase binding. A univariate regression analysis of the DElncRNAs revealed 7 lncRNAs (ADAMTS9-AS1, AC061992.1, LINC00536, HOTAIR, AL391421.1, TLR8-AS1 and LINC00491) that were associated with OS of BC patients. A multivariate Cox regression analysis demonstrated that 4 of those lncRNAs (ADAMTS9-AS1, LINC00536, AL391421.1 and LINC00491) had significant prognostic value, and their cumulative risk score indicated that this 4-lncRNA signature independently predicted OS in BC patients. Furthermore, the area under the curve of the 4-lncRNA signature associated with 3-year survival was 0.696. The current study provides novel insights into the lncRNA-related ceRNA network in BC and the 4 lncRNA biomarkers may be independent prognostic signatures in predicting the survival of BC patients.
- 11 September 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 3185-3196
Comprehensive analysis of novel three‐long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple‐negative breast cancer
Currently, traditional predictors of prognosis (tumor size, nodal status, progesterone receptor [PR], estrogen receptor [ER], or human epidermal growth factor receptor‐2 [HER2]) are insufficient for precise survival prediction for triple‐negative breast cancer (TNBC). Long noncoding RNAs (lncRNAs) have been observed to exert critical functions in cancer, including in TNBC. Nevertheless, systematically tracking expression‐based lncRNA biomarkers based on the sequence data for the prediction of prognosis in TNBC has not yet been investigated. To ascertain whether biomarkers exist that can distinguish TNBC from adjacent normal tissue or nTNBC, we implemented a comprehensive analysis of lncRNA expression profiles and clinical data of 1097 BC samples from The Cancer Genome Atlas database. A total of 1510 differentially expressed lncRNAs in normal and TNBC samples were extracted. Similarly, 672 differentially expressed lncRNAs between nTNBC and TNBC samples were detected. The receiver operating characteristic curve analysis indicated that three upregulated lncRNAs (AC091043.1, AP000924.1, and FOXCUT) may be of strong diagnostic value for predicting the existence of TNBC in the training and validation sets (area under the curve (AUC > 0.85). Kaplan‐Meier analysis demonstrated that the other three lncRNAs (AC010343.3, AL354793.1, and FGF10‐AS1) were associated with the prognosis of TNBC patients (P < 0.05). We used the three overall survival (OS)‐related lncRNAs to establish a three‐lncRNA signature. Multivariate Cox regression analysis suggested that the three‐lncRNA signature was a prognostic factor independent of other clinical variables ( P < 0.01) for predicting OS in TNBC patients that could be utilized to classify patients into high‐ or low‐risk subgroups. Our results might provide efficient signatures for clinical diagnosis and prognostic evaluation of TNBC.
- 11 September 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 3185-3196
Comprehensive analysis of novel three‐long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple‐negative breast cancer
Currently, traditional predictors of prognosis (tumor size, nodal status, progesterone receptor [PR], estrogen receptor [ER], or human epidermal growth factor receptor‐2 [HER2]) are insufficient for precise survival prediction for triple‐negative breast cancer (TNBC). Long noncoding RNAs (lncRNAs) have been observed to exert critical functions in cancer, including in TNBC. Nevertheless, systematically tracking expression‐based lncRNA biomarkers based on the sequence data for the prediction of prognosis in TNBC has not yet been investigated. To ascertain whether biomarkers exist that can distinguish TNBC from adjacent normal tissue or nTNBC, we implemented a comprehensive analysis of lncRNA expression profiles and clinical data of 1097 BC samples from The Cancer Genome Atlas database. A total of 1510 differentially expressed lncRNAs in normal and TNBC samples were extracted. Similarly, 672 differentially expressed lncRNAs between nTNBC and TNBC samples were detected. The receiver operating characteristic curve analysis indicated that three upregulated lncRNAs (AC091043.1, AP000924.1, and FOXCUT) may be of strong diagnostic value for predicting the existence of TNBC in the training and validation sets (area under the curve (AUC > 0.85). Kaplan‐Meier analysis demonstrated that the other three lncRNAs (AC010343.3, AL354793.1, and FGF10‐AS1) were associated with the prognosis of TNBC patients (P < 0.05). We used the three overall survival (OS)‐related lncRNAs to establish a three‐lncRNA signature. Multivariate Cox regression analysis suggested that the three‐lncRNA signature was a prognostic factor independent of other clinical variables ( P < 0.01) for predicting OS in TNBC patients that could be utilized to classify patients into high‐ or low‐risk subgroups. Our results might provide efficient signatures for clinical diagnosis and prognostic evaluation of TNBC.